{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:37:25Z","timestamp":1792179445882,"version":"4.4.0"},"reference-count":43,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"12","license":[{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017723","name":"Innovent Biologics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017723","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Treatment options for Chinese patients with locally advanced or metastatic squamous\u2010cell non\u2010small\u2010cell lung cancer (sqNSCLC) after failure of first\u2010line chemotherapy are limited. This study (ORIENT\u20103) aimed to evaluate the efficacy and safety of sintilimab versus docetaxel as second\u2010line treatment in patients with locally advanced or metastatic sqNSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      ORIENT\u20103 was an open\u2010label, multicenter, randomized controlled phase 3 trial that recruited patients with stage IIIB\/IIIC\/IV sqNSCLC after failure with first\u2010line platinum\u2010based chemotherapy. Patients were randomized in a 1:1 ratio to receive either 200 mg of sintilimab or 75 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      of docetaxel intravenously every 3 weeks, stratified by the Eastern Cooperative Oncology Group performance status. The primary endpoint was overall survival (OS) in the full analysis set (FAS). Secondary endpoints included progression\u2010free survival (PFS), objective response rate (ORR), disease control rate (DCR), duration of response (DoR) and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Between August 25, 2017, and November 7, 2018, 290 patients were randomized. For FAS, 10 patients from the docetaxel arm were excluded. The median OS was 11.79 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 145; 95% confidence interval [CI], 10.28\u201015.57) months with sintilimab versus 8.25 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 135; 95% CI, 6.47\u20109.82) months with docetaxel (hazard ratio [HR]: 0.74; 95% CI, 0.56\u20100.96;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.025). Sintilimab treatment significantly prolonged PFS (median 4.30 vs. 2.79 months; HR: 0.52; 95% CI, 0.39\u20100.68;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and showed higher ORR (25.50% vs. 2.20%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and DCR (65.50% vs. 37.80%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) than the docetaxel arm. The median DoR was 12.45 (95% CI, 4.86\u201025.33) months in the sintilimab arm and 4.14 (95% CI, 1.41\u20107.23) months in the docetaxel arm (\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      0.045). Treatment\u2010related adverse events of grade \u2265 3 were reported in 26 (18.1%) patients in the sintilimab arm and 47 (36.2%) patients in the docetaxel arm. Exploratory biomarker analysis showed potential predictive values of expression levels of two transcription factors, including\n                      <jats:italic toggle=\"yes\">OVOL2<\/jats:italic>\n                      (HR: 0.35;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and\n                      <jats:italic toggle=\"yes\">CTCF<\/jats:italic>\n                      (HR: 3.50;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001)\uff0cfor sintilimab treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Compared with docetaxel, sintilimab significantly improved the OS, PFS, and ORR of Chinese patients with previously treated locally advanced or metastatic sqNSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cac2.12385","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:38:40Z","timestamp":1667781520000},"page":"1314-1330","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Sintilimab versus docetaxel as second\u2010line treatment in advanced or metastatic squamous non\u2010small\u2010cell lung cancer: an open\u2010label, randomized controlled phase 3 trial (ORIENT\u20103)"],"prefix":"10.34133","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"first","affiliation":[{"name":"Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital","place":["Changsha, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Yu","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puyuan","family":"Xing","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Zhejiang University","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airong","family":"Wang","sequence":"additional","affiliation":[{"name":"Weihai Municipal Hospital","place":["Weihai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Shi","sequence":"additional","affiliation":[{"name":"Linyi Cancer Hospital","place":["Linyi, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[{"name":"General Hospital of Chinese People's Liberation Army","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziping","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Cancer Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"An","sequence":"additional","affiliation":[{"name":"Beijing Chao\u2010Yang Hospital","place":["Beijing, P. R. China"]},{"name":"Capital Medical University","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Fang","sequence":"additional","affiliation":[{"name":"Sir Run Run Shaw Hospital, Zhejiang University","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Xuzhou Medical University","place":["Xuzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6958-0766","authenticated-orcid":false,"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Shanghai Pulmonary Hospital, Tongji University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[{"name":"Fujian Medical University","place":["Xiamen, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Wang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Jining Medical University","place":["Jining, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-5393","authenticated-orcid":false,"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Hospital of China Medical University","place":["Shenyang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University","place":["Zhengzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Zhejiang University School of Medicine","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[{"name":"The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Hospital of Anhui Medical University","place":["Hefei, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Shi","sequence":"additional","affiliation":[{"name":"Shanghai Fifth\u2019 People's Hospital","place":["Shanghai, P. R. China"]},{"name":"Fudan University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[{"name":"Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute","place":["Shenyang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology","place":["Wuhan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-0877","authenticated-orcid":false,"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qisen","family":"Guo","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute","place":["Jinan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Capital Medical University","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Song","sequence":"additional","affiliation":[{"name":"The General Hospital of the Eastern Theater Command of PLA","place":["Nanjing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shucai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Tuberculosis and Thoracic Tumor Research Institute","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology","place":["Wuhan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["Changchun, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Niu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinxiang Medical University","place":["Xinxiang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Hu","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Changzhou","place":["Changzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Xingtai Medical College","place":["Xingtai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Huang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University","place":["Suzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second Hospital of Dalian Medical University","place":["Dalian, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Jilin Cancer Hospital","place":["Changchun, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengdong","family":"Wu","sequence":"additional","affiliation":[{"name":"Jiangsu Taizhou People's Hospital","place":["Taizhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Peng","sequence":"additional","affiliation":[{"name":"Innovent Biologics, Inc.","place":["Suzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiya","family":"Sun","sequence":"additional","affiliation":[{"name":"Innovent Biologics, Inc.","place":["Suzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mancao","sequence":"additional","affiliation":[{"name":"Innovent Biologics, Inc.","place":["Suzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Innovent Biologics, Inc.","place":["Suzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Sun","sequence":"additional","affiliation":[{"name":"Innovent Biologics, Inc.","place":["Suzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2022,11,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"issue":"5","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cac2.12025","article-title":"Cancer burden of major cancers in China: A need for sustainable actions","volume":"40","author":"Cao M","year":"2020","unstructured":"Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: A need for sustainable actions. Cancer Commun (Lond). 2020;40((5)):205\u201010.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccm.2011.08.005","article-title":"Pathology of lung cancer","volume":"32","author":"Travis WD","year":"2011","unstructured":"Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32((4)):669\u201092.","journal-title":"Clin Chest Med"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12153"},{"issue":"5","key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial","volume":"14","author":"Wu YL","year":"2019","unstructured":"Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, et\u00a0al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. J Thorac Oncol. 2019;14((5)):867\u201075.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40364-020-00250-z","article-title":"Recent updates on Sintilimab in solid tumor immunotherapy","volume":"8","author":"Liu X","year":"2020","unstructured":"Liu X, Yi Y. Recent updates on Sintilimab in solid tumor immunotherapy. Biomark Res. 2020;8((1)):69.","journal-title":"Biomark Res"},{"issue":"9","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab Plus Platinum and Gemcitabine as First\u2010Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double\u2010Blind, Phase 3 Trial (ORIENT\u201012)","volume":"16","author":"Zhou C","year":"2021","unstructured":"Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et\u00a0al. Sintilimab Plus Platinum and Gemcitabine as First\u2010Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double\u2010Blind, Phase 3 Trial (ORIENT\u201012). J Thorac Oncol. 2021;16((9)):1501\u201011.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First\u2010Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double\u2010Blind, Phase 3 Study (Oncology pRogram by InnovENT anti\u2010PD\u20101\u201011)","volume":"15","author":"Yang Y","year":"2020","unstructured":"Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, et\u00a0al. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First\u2010Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double\u2010Blind, Phase 3 Study (Oncology pRogram by InnovENT anti\u2010PD\u20101\u201011). J Thorac Oncol. 2020;15((10)):1636\u201046.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA\u2010seq data","volume":"14","author":"H\u00e4nzelmann S","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA\u2010seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.04.003"},{"issue":"12","key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA\u2010seq data with DESeq2","volume":"15","author":"Love MI","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA\u2010seq data with DESeq2. Genome Biol. 2014;15((12)):550.","journal-title":"Genome Biol"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2016.11.034","article-title":"Ovol2 gene inhibits the Epithelial\u2010to\u2010Mesenchymal Transition in lung adenocarcinoma by transcriptionally repressing Twist1","volume":"600","author":"Wang ZH","year":"2017","unstructured":"Wang ZH, Li Z, Hu M, Yang QJ, Yan S, Wu RS, et\u00a0al. Ovol2 gene inhibits the Epithelial\u2010to\u2010Mesenchymal Transition in lung adenocarcinoma by transcriptionally repressing Twist1. Gene. 2017;600:1\u20108.","journal-title":"Gene"},{"issue":"6","key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.celrep.2016.04.020","article-title":"OVOL2 Maintains the Transcriptional Program of Human Corneal Epithelium by Suppressing Epithelial\u2010to\u2010Mesenchymal Transition","volume":"15","author":"Kitazawa K","year":"2016","unstructured":"Kitazawa K, Hikichi T, Nakamura T, Mitsunaga K, Tanaka A, Nakamura M, et\u00a0al. OVOL2 Maintains the Transcriptional Program of Human Corneal Epithelium by Suppressing Epithelial\u2010to\u2010Mesenchymal Transition. Cell Rep. 2016;15((6)):1359\u201068.","journal-title":"Cell Rep"},{"issue":"4","key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000456534","article-title":"Post\u2010Progression Survival Associated with Overall Survival in Patients with Advanced Non\u2010Small\u2010Cell Lung Cancer Receiving Docetaxel Monotherapy as Second\u2010Line Chemotherapy","volume":"62","author":"Kotake M","year":"2017","unstructured":"Kotake M, Miura Y, Imai H, Mori K, Sakurai R, Kaira K, et\u00a0al. Post\u2010Progression Survival Associated with Overall Survival in Patients with Advanced Non\u2010Small\u2010Cell Lung Cancer Receiving Docetaxel Monotherapy as Second\u2010Line Chemotherapy. Chemotherapy. 2017;62((4)):205\u201013.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00209-0"},{"issue":"9944","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second\u2010line treatment of stage IV non\u2010small\u2010cell lung cancer after disease progression on platinum\u2010based therapy (REVEL): a multicentre, double\u2010blind, randomised phase 3 trial","volume":"384","author":"Garon EB","year":"2014","unstructured":"Garon EB, Ciuleanu T\u2010E, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et\u00a0al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second\u2010line treatment of stage IV non\u2010small\u2010cell lung cancer after disease progression on platinum\u2010based therapy (REVEL): a multicentre, double\u2010blind, randomised phase 3 trial. Lancet (London, England). 2014;384((9944)):665\u201073.","journal-title":"Lancet (London, England)"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"issue":"43","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"E10119","DOI":"10.1073\/pnas.1802166115","article-title":"Differential regulation of PD\u2010L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti\u2010PD\u2010L1)","volume":"115","author":"Kowanetz M","year":"2018","unstructured":"Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, et\u00a0al. Differential regulation of PD\u2010L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti\u2010PD\u2010L1). Proc Natl Acad Sci. 2018;115((43)):E10119\u2010e26.","journal-title":"Proc Natl Acad Sci"},{"issue":"19","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD\u2010L1\u2010Positive Non\u2010Small\u2010Cell Lung Cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez\u2010Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et\u00a0al. Pembrolizumab versus Chemotherapy for PD\u2010L1\u2010Positive Non\u2010Small\u2010Cell Lung Cancer. N Engl J Med. 2016;375((19)):1823\u201033.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD\u2010L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis AA","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD\u2010L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7((1)):278.","journal-title":"J Immunother Cancer"},{"issue":"17","key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2217\/imt-2019-0101","article-title":"The efficacy of PD\u20101\/PD\u2010L1 inhibitors in advanced squamous\u2010cell lung cancer: a meta\u2010analysis of 3112 patients","volume":"11","author":"Chen R\u2010L","year":"2019","unstructured":"Chen R\u2010L, Zhou J\u2010X, Cao Y, Li S\u2010H, Li Y\u2010H, Jiang M, et\u00a0al. The efficacy of PD\u20101\/PD\u2010L1 inhibitors in advanced squamous\u2010cell lung cancer: a meta\u2010analysis of 3112 patients. Immunotherapy. 2019;11((17)):1481\u201090.","journal-title":"Immunotherapy"},{"issue":"10066","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non\u2010small\u2010cell lung cancer (OAK): a phase 3, open\u2010label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer A","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et\u00a0al. Atezolizumab versus docetaxel in patients with previously treated non\u2010small\u2010cell lung cancer (OAK): a phase 3, open\u2010label, multicentre randomised controlled trial. Lancet. 2017;389((10066)):255\u201065.","journal-title":"Lancet"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw289"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2018.09.004"},{"issue":"2","key":"e_1_3_2_29_2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37120","article-title":"Association of Performance Status With Survival in Patients With Advanced Non\u2010Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy","volume":"4","author":"Sehgal K","year":"2021","unstructured":"Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M, et\u00a0al. Association of Performance Status With Survival in Patients With Advanced Non\u2010Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw Open. 2021;4((2)):e2037120.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","article-title":"ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2010A systematic review and meta\u2010analysis of real world data","volume":"145","author":"Dall'Olio FG","year":"2020","unstructured":"Dall'Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A. ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2010A systematic review and meta\u2010analysis of real world data. Lung Cancer. 2020;145:95\u2010104.","journal-title":"Lung Cancer"},{"issue":"1","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12957-020-1792-4","article-title":"Smokers or non\u2010smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up\u2010to\u2010date meta\u2010analysis","volume":"18","author":"Mo J","year":"2020","unstructured":"Mo J, Hu X, Gu L, Chen B, Khadaroo PA, Shen Z, et\u00a0al. Smokers or non\u2010smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up\u2010to\u2010date meta\u2010analysis. World J Surg Oncol. 2020;18((1)):15.","journal-title":"World J Surg Oncol"},{"issue":"4","key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.4143\/crt.2015.401","article-title":"East Asian Subgroup Analysis of a Randomized, Double\u2010Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non\u2010small Cell Lung Cancer Following Disease Progression after One Prior Platinum\u2010Based Therapy (REVEL)","volume":"48","author":"Park K","year":"2016","unstructured":"Park K, Kim J\u2010H, Cho EK, Kang J\u2010H, Shih J\u2010Y, Zimmermann AH, et\u00a0al. East Asian Subgroup Analysis of a Randomized, Double\u2010Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non\u2010small Cell Lung Cancer Following Disease Progression after One Prior Platinum\u2010Based Therapy (REVEL). Cancer Res Treat. 2016;48((4)):1177\u201086.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2012.10.015","article-title":"Second\u2010line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non\u2010small cell lung cancer: a randomized, open\u2010label study","volume":"79","author":"Sun Y","year":"2013","unstructured":"Sun Y, Wu YL, Zhou CC, Zhang L, Zhang L, Liu XY, et\u00a0al. Second\u2010line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non\u2010small cell lung cancer: a randomized, open\u2010label study. Lung cancer. 2013;79((2)):143\u201050.","journal-title":"Lung cancer"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: A Promising Anti\u2010Tumor PD\u20101 Antibody","volume":"10","author":"Zhang L","year":"2020","unstructured":"Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: A Promising Anti\u2010Tumor PD\u20101 Antibody. Front Oncol. 2020;10:594558.","journal-title":"Front Oncol"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02738-x"},{"issue":"7","key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jtho.2021.03.016","article-title":"Efficacy and Safety of First\u2010Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta\u2010Analysis","volume":"16","author":"Liu L","year":"2021","unstructured":"Liu L, Bai H, Wang C, Seery S, Wang Z, Duan J, et\u00a0al. Efficacy and Safety of First\u2010Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta\u2010Analysis. J Thorac Oncol. 2021;16((7)):1099\u2010117.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3663"},{"issue":"1","key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13059-020-02152-7","article-title":"Cancer\u2010specific CTCF binding facilitates oncogenic transcriptional dysregulation","volume":"21","author":"Fang C","year":"2020","unstructured":"Fang C, Wang Z, Han C, Safgren SL, Helmin KA, Adelman ER, et\u00a0al. Cancer\u2010specific CTCF binding facilitates oncogenic transcriptional dysregulation. Genome Biol. 2020;21((1)):247.","journal-title":"Genome Biol"},{"issue":"7","key":"e_1_3_2_39_2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2120540119","article-title":"Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD\u2010L1","volume":"119","author":"Oreskovic E","year":"2022","unstructured":"Oreskovic E, Wheeler EC, Mengwasser KE, Fujimura E, Martin TD, Tothova Z, et\u00a0al. Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD\u2010L1. Proc Natl Acad Sci. 2022;119((7)):e2120540119.","journal-title":"Proc Natl Acad Sci"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2688"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657483","article-title":"Circulating Tumor DNA Analyses Predict Disease Recurrence in Non\u2010Muscle\u2010Invasive Bladder Cancer","volume":"11","author":"Zhang J","year":"2021","unstructured":"Zhang J, Dai D, Tian J, Li L, Bai J, Xu Y, et\u00a0al. Circulating Tumor DNA Analyses Predict Disease Recurrence in Non\u2010Muscle\u2010Invasive Bladder Cancer. Front Oncol. 2021;11:657483.","journal-title":"Front Oncol"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-020-00707-9"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JIR.S343432","article-title":"Tumor\u2010Infiltrating CD4 Central Memory T Cells Correlated with Favorable Prognosis in Oral Squamous Cell Carcinoma","volume":"15","author":"Wu J","year":"2022","unstructured":"Wu J, Zhang T, Xiong H, Zeng L, Wang Z, Peng Y, et\u00a0al. Tumor\u2010Infiltrating CD4 Central Memory T Cells Correlated with Favorable Prognosis in Oral Squamous Cell Carcinoma. J Inflamm Res. 2022;15:141\u201052.","journal-title":"J Inflamm Res"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077322"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cac2.12385","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cac2.12385","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.12385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:52:33Z","timestamp":1773823953000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.12385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,6]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1002\/cac2.12385"],"URL":"https:\/\/doi.org\/10.1002\/cac2.12385","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,6]]},"assertion":[{"value":"2021-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}